Under the agreement Dalton will continue to provide chemistry services in support of Boehringer’s pharmaceutical development programs.
Peter Pekos, president of Dalton Pharma Services, said: “We are extremely pleased to continue our relationship with Boehringer Ingelheim Canada. The renewal of our chemistry services agreement demonstrates Boehringer Ingelheim’s deep commitment to research in Canada. We look forward to another successful collaboration with this world-class organization.”